NASDAQ:CBMG - Cellular Biomedicine Group Stock Price, News, & Analysis

Cellular Biomedicine Group trades on the NASDAQ under the ticker symbol "CBMG."

Cellular Biomedicine Group declared that its board has initiated a share repurchase program on Sunday, June 4th 2017, which permits the company to buyback $10,000,000.00 in outstanding shares, according to EventVestor. This buyback authorization permits the company to buy shares of its stock through open market purchases. Stock buyback programs are often a sign that the company's leadership believes its stock is undervalued.

Cellular Biomedicine Group Inc (NASDAQ:CBMG) released its earnings results on Tuesday, November, 6th. The biotechnology company reported ($0.56) earnings per share for the quarter, missing the Zacks' consensus estimate of ($0.52) by $0.04. The biotechnology company earned $0.07 million during the quarter, compared to analysts' expectations of $0.05 million. Cellular Biomedicine Group had a negative net margin of 13,988.39% and a negative return on equity of 44.62%. View Cellular Biomedicine Group's Earnings History.

Cellular Biomedicine Group is scheduled to release their next quarterly earnings announcement on Tuesday, March 5th 2019. View Earnings Estimates for Cellular Biomedicine Group.

2 brokerages have issued 12-month price targets for Cellular Biomedicine Group's shares. Their forecasts range from $38.00 to $38.00. On average, they expect Cellular Biomedicine Group's stock price to reach $38.00 in the next year. This suggests a possible upside of 101.0% from the stock's current price. View Analyst Price Targets for Cellular Biomedicine Group.

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Cellular Biomedicine Group in the last year. There are currently 1 hold rating and 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Cellular Biomedicine Group.

News stories about CBMG stock have trended somewhat positive on Saturday, according to InfoTrie. InfoTrie identifies positive and negative media coverage by analyzing more than six thousand news and blog sources. The firm ranks coverage of companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Cellular Biomedicine Group earned a coverage optimism score of 1.7 on InfoTrie's scale. They also gave news stories about the biotechnology company a news buzz of 1.0 out of 10, indicating that recent media coverage is extremely unlikely to have an impact on the company's share price in the near future.

Some companies that are related to Cellular Biomedicine Group include Editas Medicine (EDIT), Autolus Therapeutics (AUTL), Momenta Pharmaceuticals (MNTA), Iovance Biotherapeutics (IOVA), Sangamo Therapeutics (SGMO), Rubius Therapeutics (RUBY), Orchard Therapeutics (ORTX), Fate Therapeutics (FATE), Audentes Therapeutics (BOLD), BioCryst Pharmaceuticals (BCRX), Solid Biosciences (SLDB), Novavax (NVAX), Acorda Therapeutics (ACOR), Vericel (VCEL) and Coherus Biosciences (CHRS).

Cellular Biomedicine Group's stock is owned by a number of of institutional and retail investors. Top institutional shareholders include Meeder Asset Management Inc. (0.02%). Company insiders that own Cellular Biomedicine Group stock include Andrew K Chan, Tony Liu, Wen Tao Liu and Yihong Yao. View Institutional Ownership Trends for Cellular Biomedicine Group.

CBMG stock was bought by a variety of institutional investors in the last quarter, including Meeder Asset Management Inc.. Company insiders that have bought Cellular Biomedicine Group stock in the last two years include Andrew K Chan, Tony Liu and Yihong Yao. View Insider Buying and Selling for Cellular Biomedicine Group.

Shares of CBMG can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

One share of CBMG stock can currently be purchased for approximately $18.91.

Cellular Biomedicine Group has a market capitalization of $369.95 million and generates $340,000.00 in revenue each year. The biotechnology company earns $-25,490,000.00 in net income (profit) each year or ($1.78) on an earnings per share basis. Cellular Biomedicine Group employs 125 workers across the globe.

The official website for Cellular Biomedicine Group is http://www.cellbiomedgroup.com.

Cellular Biomedicine Group's mailing address is 19925 STEVENS CREEK BLVD. SUITE 100, CUPERTINO CA, 95014. The biotechnology company can be reached via phone at 408-973-7884 or via email at [email protected]